Clinical trial
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's…
NCT00238238 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00238238 |
|---|---|
| Title | Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab |
| Official title | A Randomized Phase II Trial of Rituximab Versus Lenalidomide (REVLIMID™, Cc-5013) (IND#73034) Versus Rituximab + Lenalidomide in Recurrent Follicular Non-Hodgkin Lymphoma (NHL) That is Not Rituximab-Refractory |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological, Drug |
| Interventions | rituximab, lenalidomide |
| Enrollment | 97 |
| Start date | Mar 1, 2006 |
| Primary completion | Jun 1, 2012 |
| Completion | Aug 1, 2015 |
| First posted | Oct 13, 2005 |
| Last update posted | Mar 15, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: